Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome

作者：Lee Min Goo; Jeong Myung Ho^*; Ahn Youngkeun; Cho Jeong Gwan; Park Jong Chun; Kang Jung Chaee; Chae Shung Chull; Hur Seung Ho; Hong Taek Jong; Kim Young Jo; Seong In Whan; Chae Jei Keon; Rhew Jay Young; Chae In Ho; Cho Myeong Chan; Bae Jang Ho; Rha Seung Woon; Kim Chong Jin; Choi Donghoon; Jang Yang Soo; Yoon Junghan; Chung Wook Sung; Seung Ki Bae; Park Seung Jung

来源：Circulation Journal, 2011, 75(9): 2120-2127.

DOI：10.1253/circj.CJ-11-0263

• Drug-eluting stent
• Metabolic syndrome
• Myocardial infarction

Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS).
Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (all-cause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448).
Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR. (Circ J 2011; 75: 2120-2127)

• 出版日期2011-9